

Original Research Article

Metabolic Role Of Leptin In Gestational Diabetes Mellitus

Usha Adiga^{1*}^{1*}Professor, Department of Biochemistry, KS Hegde Medical Academy, NITTE (DU), Mangalore.

*Corresponding author: Dr Usha Adiga

*Professor, Department of Biochemistry, KS Hegde Medical Academy, NITTE (DU), Mangalore. Email ID- ushachidu@yahoo.com

Abstract

Adipose tissue acts as an endocrine gland, produce various adipokines which help in establishing communication between adipose tissue and other organs. Leptin is an important adipokine, mediating a wide range of functions like lipid and carbohydrate metabolism, insulin sensitivity, atherosclerosis, angiogenesis etc. Gestational diabetes mellitus (GDM) is a complication of pregnancy which is characterized by impaired carbohydrate tolerance with onset or first recognition during pregnancy. It develops as a result of decreased insulin sensitivity and results in altered metabolic effects like increased postprandial FFAs, increased hepatic glucose production high blood glucose levels. Leptin levels are reported to be altered, may be increased or decreased in GDM. However, report available are conflicting and fact is yet to be established. Insulin resistance in GDM has been associated with elevated leptin levels. As leptin is closely associated with lipid metabolism, it may be attributed dyslipidemias in GDM. As leptin has a wide range of metabolic roles, it may have an impact on pregnancy outcomes, both maternal as well as fetal, it is an important topic to review.

Overview

Leptin is an adipokine, secreted from adipocytes, which influences various metabolic functions. It is involved in regulation of energy intake and expenditure, influences carbohydrate metabolism by enhancing insulin secretion and sensitivity, glucose utilization, glycogen synthesis. Leptin also has an important role lipid metabolism and associated with obesity.

Gestational diabetes mellitus is defined as glucose intolerance of varying severity with onset or first recognition during pregnancy [1]. Prevalence of GDM is 7% of all pregnancies in the world. A study by Choudhary *et al* reported a prevalence of 9% of GDM in India [2].

Leptin Gene polymorphisms in Gestational diabetes

Zhang *et al*, in their meta-analysis, have narrated the role of polymorphisms of genes in GDM[3]. However, there are only few studies on polymorphism of leptin gene in GDM to the best of our knowledge. Study by Hoffstedt *et al* reported an association between LEP G2548A polymorphism and elevated leptin levels [4]. The relationship between polymorphisms of leptin as well as its receptor with type 2 diabetes mellitus is well established [5,6]. Yang *et al* studied both leptin gene and its receptor polymorphism in Chinese population [7], however they didn't find any significant association between leptin gene polymorphism and GDM. Genetic polymorphisms may vary from population to population. There are no such reports available in Indian population.

Previous studies have reported LEP G2548A polymorphism had a strong influence on leptin gene expression [8-10], inconsistent with the results in Egyptian study by Abdel [11] and Romanian study

by Constantin *et al* [6]. An association between *LEPR* Gln223Arg gene polymorphism and leptin levels was found in Thai population studied by Suriyaprom *et al* [10], Dutch population by Rossum *et al* [12] and Romanian subjects by Constantin *et al* [6]. However, no such association was found in Turkish subjects studied by Ornek *et al* [13] and in Chinese population investigated by Yang *et al* [7], Heo [14]. But other studies suggested that *LEPR* Gln223Arg polymorphism was associated with higher insulin resistance and BMI [15].

Study by Vasku *et al* opined that subjects with AA and AG genotypes, due to their higher transcriptional activity of the *LEP* gene, have a significantly higher risk for gestational diabetes mellitus against those carrying the GG genotype [16]. This finding supports the hypothesis of leptin involvement in etiopathogenesis of GDM. Study by Pawlik *et al* suggested that women with the *LEP* rs2167270, A allele had an increased daily insulin requirement suggesting a severe form of GDM [17]. Research by Sahin *et al.* and Mammès *et al.* suggested that the *LEP* rs2167270 A allele is associated with increased serum leptin levels [18,19]. Hoffstedt *et al.* have shown that the rs2167270 leptin gene polymorphism influences leptin expression at the transcriptional level and hence affects the secretion of this hormone [8].

The *leptin (LEP)* G2548A polymorphism was found to be associated with increased leptin production and plasma secretion from adipocytes. Mutation in *leptin receptor (LEPR)* Gln223Arg results in impaired signaling capacity of leptin receptor [8]. Plasma leptin levels and placental leptin expression in women with GDM were significantly increased in comparison with healthy pregnant women [20,21]. Hence polymorphisms of leptin and its receptor gene could result in altered expression of their proteins.

Serum Leptin levels in Gestational diabetes

Plasma leptin levels are reported to be higher in pregnancy, peak being at 28 weeks of gestation compared to non-pregnant status. However, reports on leptin levels in GDM has been conflicting so far, as some reports suggest an elevated leptin levels [22,23], decreased [24] whereas some suggest an unaltered leptin levels in GDM [25]. So it is interesting study leptin levels of GDM patients in Indian population.

In pregnancy, due to the increased fat mass and the presence of placenta, maternal leptin concentrations increase 2 to 3-fold above non-pregnant concentration, with the peak occurring around 28 weeks of gestation. As leptin may have a major role in maternal metabolism and maternal glucose homeostasis regulation, plasma leptin levels may be an important marker for predicting GDM. However, reports available on the levels of maternal leptin in GDM, are conflicting. Studies have reported an elevated leptin levels in GDM [22,23,26], diminished leptin levels [24] or insignificant differences in leptin levels among GDM patients compared to controls [25]. A study by Nouraldeem *et al.* reported no significant change in leptin levels at 2nd trimester but diminished leptin levels at the 3rd trimester among GDM patients [27]. Qiu and colleagues, in their cohort study showed that for each 10 ng/ml increase in the leptin levels in early pregnancy was associated with a 20% increase in GDM risk [28]. Kautzky-Willer *et al.*, in a case control study, found that plasma leptin concentrations were higher in GDM women compared with the control group in the third-trimester [22]. Such a relation was also found in the Vitoratus *et al* [29] and Qiu *et al* [23] studies. Liu *et al* [30] showed that serum leptin level is correlated with glucose tolerance during pregnancy. However, Festa *et al* [24], in a case-control study, noted that maternal third-trimester leptin concentrations were significantly lower in GDM cases as compared with controls after adjusting for possible confounding factors, such as BMI and insulin concentrations. Several possible explanations are suggested for the disparities in the existing studies.

Pregnancy is considered to be leptin resistant state, which is associated with impaired leptin signaling. One possible function of increased maternal leptin levels is to enhance the mobilization of maternal fat stores to increase availability and to support trans-placental transfer of lipid substrates . There is a strong evidence that suggest placenta is the main contributor of plasma leptin rather than the adipose tissue . The fetus may be contributing to the maternal leptin load from early second trimester.

Gestational diabetes, Insulin resistance and Leptin

Insulin resistance is the key factor in the development of GDM. Reduced maternal pregravid insulin sensitivity coupled with inadequate insulin response are the causative factors for GDM.

Clinical study reports suggest that elevation of leptin levels are due to upregulation of leptin gene due to insulin resistance and hyperinsulinemia [31,32]. It has been reported that leptin affects whole body insulin sensitivity by regulating insulin mediated glucose metabolism by skeletal muscle as well as hepatic regulation of gluconeogenesis. Leptin has been found to have inhibitory effect on insulin secretion. Hence it is justifiable to study the association of Leptin gene polymorphism, circulating Leptin levels and insulin resistance in GDM.

Previous studies have suggested that leptin has an inhibitory effect on insulin gene expression and insulin secretion in pancreatic β -cells. Leptin also suppresses insulin secretion induced by cAMP, glucagon-like peptide 1 and protein kinase C . Moreover, leptin inhibits the phosphorylation of glucose transporter 2 (GLUT2) and impairs glucose transport in tissues increasing insulin resistance . It has been suggested that as gestation progresses, insulin secretion increases, reaching a maximum in the third trimester [33], whereas insulin sensitivity decreases progressively by about 70% [34]. In normal pregnancy, pancreatic beta cells compensate for the increased insulin resistance to control blood glucose [35]. However, in a pregnancy complicated by GDM, reduced insulin secretion capacity and the physiological insulin resistance that occurs on a background of chronic insulin resistance, lead to a deterioration of glucose tolerance. Studies have shown that impaired beta cell function in women with GDM is mainly attributed to decreased early-phase insulin secretion . Moreover, when insulin secretion was adjusted for the degree of insulin resistance, women with GDM had severe reduction in beta-cell function compared to normal pregnant women [36]. Ryan *et al.* demonstrated increased insulin resistance in women with GDM [37]. They reported a decrease in glucose infusion rate during euglycaemic clamp in women with GDM by 40-60% compared to pregnant non-diabetic controls and by 60-70% compared to nonpregnant controls [37]. Furthermore, increased endogenous glucose production has been reported in women with GDM compared to healthy pregnant controls [33,36]. Leptin directly affects pancreatic β -cell gene expression and leads to decrease insulin secretion [38]. Furthermore, leptin affects the β -cell proliferation, apoptosis, and cell growth. Leptin suppresses the expression of preproinsulin mRNA in pancreatic β -cells. Several signaling pathways are involved in this inhibitory role of leptin in insulin secretion.

Compared with the NGT group, higher leptin levels were found in the IFG group, consistent with the previous study [28]. Similarly, significantly higher fasting insulin levels, HOMA-IR and lower QUICKI were also noted in IFG and IGT group, namely impaired fasting glucose individuals, than NGT group. A positive and negative correlations were found between plasma leptin levels and HOMA-IR and QUICKI respectively. These correlations were confirmed in some studies [39,40], but contradicted in a few studies [41].

Influence of Leptin and Lipid parameters in Gestational diabetes

GDM is known to pose a significant risk in the development cardiovascular disease(CVD) in later life. The exact mechanism is yet to be established. Altered leptin levels in GDM may play a key role in promoting CVD. Reports by Jaramillo *et al* explained the influence of leptin on body weight and percentage body fat, thereby its role in regulating adiposity signals to the brain [42]. High leptin levels have been associated with high BMI and insulin resistance in type 2 DM [43]. Bodary *et al* demonstrated atherogenic role of leptin in apoE deficient mice [44]. Study by Lekva *et al* [45] reported an elevated leptin levels associated with high TG/HDL-C ratio. Altered leptin levels along with insulin resistance in GDM patients may alter their lipid levels.

Dyslipidemia in pregnancy is well documented. After an initial decrease in the first trimester, there is a steady increase in triacylglycerols, fatty acids, cholesterol, lipoproteins, and phospholipids. The higher concentration of estrogen and insulin resistance are thought to be responsible for the hypertriglyceridemia of pregnancy.

In a study by Nawal *et al*, total cholesterol, HDL cholesterol, and apolipoprotein concentrations were not significantly different between GDM patients and control subjects[46]. The results showed that there was positive correlation between leptin with cholesterol, triglyceride, and VLDL in over weight group and in obese group. The negative correlation was found between leptin with HDL in obese group [46].

Leptin synthesis is induced by hyperglycemia, hyperlipidemia, and a replete fat mass and also leptin suppresses insulin production . Leptin is expressed predominantly by adipocyte, which fits the idea that body weight is sensed as a total mass of fat in the body . Serum leptin concentration is increased in obese subjects and is closely related to fat mass and BMI and declines with weight loss . Leptin plays a central role in the long-term maintenance of weight homeostasis by acting on the hypothalamus to decrease food intake and increase energy expenditure . Serum leptin was positively & strongly correlated with BMI which is an important index of obesity. Similar correlation was reported by previous studies [47]. Positive correlation was noted between leptin & TG, negative correlation between HDL and leptin .

CONCLUSION

It could be concluded that, there may be a significant association between the gene polymorphisms of leptin and its receptor, altering leptin levels which in turn can alter insulin secretion and insulin resistance, contributing for dyslipidemias of pregnancy as well as gestational diabetes.

REFERENCES:

1. Metzger BE, Buchanan TA, Coustan DR, De Leiva A, Dunger DB, Hadden DR, Hod M, Kitzmiller JL, Kjos SL, Oats JN, Pettitt DJ. Summary and recommendations of the fifth international workshop-conference on gestational diabetes mellitus. *Diabetes care*. 2007;30(2):S251-60.
2. Choudhary N, Rasheed M, Aggarwal V. Prevalence of gestational diabetes mellitus, maternal and neonatal outcomes in a peripheral hospital in North India. *Int J Res Med Sci*. 2017;5(6):2343-5.
3. Zhang C, Bao W, Rong Y, Yang H, Bowers K, Yeung E, Kiely M. Genetic variants and the risk of gestational diabetes mellitus: a systematic review. *Human reproduction update*. 2013;19(4):376-90.

4. Hoffstedt J, Eriksson P, Mottagui-Tabar S, Arner P. A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. *Hormone and metabolic research*. 2002;34(07):355-9.
5. Mammes O, Betoulle D, Aubert R, Giraud V, Tuzet S, Petiet A, Colas-Linhart N, Fumeron F. Novel polymorphisms in the 5' region of the LEP gene: association with leptin levels and response to low-calorie diet in human obesity. *Diabetes*. 1998 ;47(3):487-9.
6. Constantin A, Costache G, Sima AV, Glavce CS, Vladica M, Popov DL. Leptin G-2548A and leptin receptor Q223R gene polymorphisms are not associated with obesity in Romanian subjects. *Biochemical and biophysical research communications*. 2010;391(1):282-6.
7. Yang M, Peng S, Li W, Wan Z, Fan L, Du Y. Relationships between plasma leptin levels, leptin G2548A, leptin receptor Gln223Arg polymorphisms and gestational diabetes mellitus in Chinese population. *Scientific reports*. 2016;6(1):1-6.
8. Hoffstedt J, Eriksson P, Mottagui-Tabar S, Arner P. A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. *Hormone and metabolic research*. 2002;34(07):355-9.
9. Furusawa T, Naka I, Yamauchi T, Natsuhara K, Kimura R, Nakazawa M, Ishida T, Nishida N, Eddie R, Ohtsuka R, Ohashi J. The serum leptin level and body mass index in Melanesian and Micronesian Solomon Islanders: focus on genetic factors and urbanization. *American Journal of Human Biology*. 2011;23(4):435-44.
10. Suriyaprom K, Tungtrongchitr R, Thawnasom K. Measurement of the levels of leptin, BDNF associated with polymorphisms LEP G2548A, LEPR Gln223Arg and BDNF Val66Met in Thai with metabolic syndrome. *Diabetology & metabolic syndrome*. 2014;6(1):6.
11. Abdel Hay RM, Rashed LA. Association between the leptin gene 2548G/A polymorphism, the plasma leptin and the metabolic syndrome with psoriasis. *Experimental dermatology*. 2011;20(9):715-9.
12. Van Rossum CT, Hoebee B, Van Baak MA, Mars M, Saris WH, Seidell JC. Genetic variation in the leptin receptor gene, leptin, and weight gain in young Dutch adults. *Obesity research*. 2003;11(3):377-86.
13. Komsu-Ornek Z, Demirel F, Dursun A, Ermis B, Piskin E, Bideci A. Leptin receptor gene Gln223Arg polymorphism is not associated with obesity and metabolic syndrome in Turkish children. *Turk J Pediatr*. 2012;54(1):20-4.
14. Heo M, Leibel RL, Fontaine KR, Boyer BB, Chung WK, Koulu M, Karvonen MK, Pesonen U, Rissanen A, Laakso M, Uusitupa MI. A meta-analytic investigation of linkage and association of common leptin receptor (LEPR) polymorphisms with body mass index and waist circumference. *International journal of obesity*. 2002;26(5):640-6.
15. Boumaiza I, Omezzine A, Rejeb J, Rebhi L, Ouedrani A, Ben Rejeb N, Nabli N, Ben Abdelaziz A, Bouslama A. Relationship between leptin G2548A and leptin receptor Q223R gene

- polymorphisms and obesity and metabolic syndrome risk in Tunisian volunteers. Genetic testing and molecular biomarkers. 2012;16(7):726-33.
16. Vaškù JA, Vaškù A, Dostálová Z, Bienert P. Association of leptin genetic polymorphism-2548 G/A with gestational diabetes mellitus. *Genes & nutrition*. 2006;1(2):117-23.
 17. Pawlik A, Teler J, Maciejewska A, Sawczuk M, Safranow K, Dziedziejko V. Adiponectin and leptin gene polymorphisms in women with gestational diabetes mellitus. *Journal of assisted reproduction and genetics*. 2017;34(4):511-6.
 18. Sahin DS, Tumer C, Demir C, Celik MM, Celik M, Ucar E, Gunesacar R. Association with leptin gene C.-2548 G> A polymorphism, serum leptin levels, and body mass index in Turkish obese patients. *Cell biochemistry and biophysics*. 2013;65(2):243-7.
 19. Mammes O, Betoulle D, Aubert R, Herbeth B, Siest G, Fumeron F. Association of the G-2548A polymorphism in the 5' region of the LEP gene with overweight. *Annals of human genetics*. 2000;64(5):391-4.
 20. Endo S, Maeda K, Suto M, Kaji T, Morine M, Kinoshita T, Yasui T, Irahara M. Differences in insulin sensitivity in pregnant women with overweight and gestational diabetes mellitus. *Gynecological endocrinology*. 2006;22(6):343-9.
 21. Ozcimen EE, Uckuyu A, Ciftci FC, Yanik FF, Bakar C. Diagnosis of gestational diabetes mellitus by use of the homeostasis model assessment–insulin resistance index in the first trimester. *Gynecological Endocrinology*. 2008;24(4):224-9.
 22. Kautzky-Willer A, Pacini G, Tura A, Biegelmayer C, Schneider B, Ludvik B, Prager R, Waldhäusl W. Increased plasma leptin in gestational diabetes. *Diabetologia*. 2001;44(2):164-72.
 23. Gao XL, Yang HX, Yi ZH. Variations of tumor necrosis factor- α , leptin and adiponectin in mid-trimester of gestational diabetes mellitus. *Chinese medical journal*. 2008;121(8):701-5.
 24. Festa A, Shnawa N, Krugluger W, Hopmeier P, Schernthaner G, Haffner SM. Relative hypoleptinaemia in women with mild gestational diabetes mellitus. *Diabetic medicine*. 1999;16(8):656-62.
 25. Simmons D, Breier BH. Fetal overnutrition in polynesian pregnancies and in gestational diabetes may lead to dysregulation of the adipoinular axis in offspring. *Diabetes Care*. 2002;25(9):1539-44.
 26. McLachlan KA, O'Neal D, Jenkins A, Alford FP. Do adiponectin, TNF α , leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. *Diabetes/metabolism research and reviews*. 2006;22(2):131-8.
 27. Noureldeen AF, Qusti SY, Al-seeni MN, Bagais MH. Maternal leptin, adiponectin, resistin, visfatin and tumor necrosis factor-alpha in normal and gestational diabetes. *Indian Journal of Clinical Biochemistry*. 2014;29(4):462-70.

28. Qiu C, Williams MA, Vadachkoria S, Frederick IO, Luthy DA. Increased maternal plasma leptin in early pregnancy and risk of gestational diabetes mellitus. *Obstetrics & Gynecology*. 2004;103(3):519-25.
29. Vitoratos N, Salamalekis E, Kassanos D, Loghis C, Panayotopoulos N, Kouskouni E, Creatsas G. Maternal plasma leptin levels and their relationship to insulin and glucose in gestational-onset diabetes. *Gynecologic and obstetric investigation*. 2001;51(1):17-21.
30. Liu ZJ, Liu PQ, Ding Y, Wang AM, Zhang JJ, Zhao XF. Maternal plasma leptin levels and their relationship to insulin and glucose in pregnant women with gestational diabetes mellitus and gestational impaired glucose tolerance. *Zhonghua fu chan ke za zhi*. 2003;38(5):261-3.
31. Gross GA, Solenberger T, Philpott T, Holcomb WL, Landt M. Plasma leptin concentrations in newborns of diabetic and nondiabetic mothers. *American journal of perinatology*. 1998;11(04):243-7.
32. Laivuori H, Kaaja R, Koistinen H, Karonen SL, Andersson S, Koivisto V, Ylikorkala O. Leptin during and after preeclamptic or normal pregnancy: its relation to serum insulin and insulin sensitivity. *Metabolism*. 2000;49(2):259-63.
33. Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. *American journal of obstetrics and gynecology*. 1999;180(4):903-16.
34. Sivan E, Homko CJ, Chen X, Reece EA, Boden G. Effect of insulin on fat metabolism during and after normal pregnancy. *Diabetes*. 1999;48(4):834-8.
35. Catalano PM, Tyzbir ED, Wolfe RR, Roman NM, Amini SB, Sims EA. Longitudinal changes in basal hepatic glucose production and suppression during insulin infusion in normal pregnant women. *American journal of obstetrics and gynecology*. 1992;167(4):913-9.
36. Xiang AH, Peters RK, Trigo E, Kjos SL, Lee WP, Buchanan TA. Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes. *Diabetes*. 1999;48(4):848-54.
37. Ryan EA, O'Sullivan MJ, Skyler JS. Insulin action during pregnancy: studies with the euglycemic clamp technique. *Diabetes*. 1985;34(4):380-9.
38. Seufert J, Kieffer TJ, Habener JF. Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. *Proceedings of the National Academy of Sciences*. 1999;96(2):674-9.
39. Endo S, Maeda K, Suto M, Kaji T, Morine M, Kinoshita T, Yasui T, Irahara M. Differences in insulin sensitivity in pregnant women with overweight and gestational diabetes mellitus. *Gynecological endocrinology*. 2006;22(6):343-9.
40. Ozcimen EE, Uckuyu A, Ciftci FC, Yanik FF, Bakar C. Diagnosis of gestational diabetes mellitus by use of the homeostasis model assessment-insulin resistance index in the first trimester. *Gynecological Endocrinology*. 2008;24(4):224-9.

41. López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, Triana-Cubillos S. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. *Hormone molecular biology and clinical investigation*. 2014;18(1):37-45.
42. Hou N, Luo JD. Leptin and cardiovascular diseases. *Clinical and Experimental Pharmacology and Physiology*. 2011;38(12):905-13.
43. Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM, Eitzman DT. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. *Arteriosclerosis, thrombosis, and vascular biology*. 2005;25(8):e119-22.
44. Lekva T, Michelsen AE, Aukrust P, Henriksen T, Bollerslev J, Ueland T. Leptin and adiponectin as predictors of cardiovascular risk after gestational diabetes mellitus. *Cardiovascular diabetology*. 2017;16(1):5.
45. Yilmaz O, Kucuk M, Ilgin A, Dagdelen M. Assessment of insulin sensitivity/resistance and their relations with leptin concentrations and anthropometric measures in a pregnant population with and without gestational diabetes mellitus. *Journal of Diabetes and its Complications*. 2010;24(2):109-14
46. Murtadha NA, Sarhat ER. Relationship between leptin and lipid profile in obese females in tikrit province. *Int J Curr Microbiol App Sci*. 2016;5(5):493-501.
47. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS. Role of leptin in the neuroendocrine response to fasting. *Nature*. 1996;382(6588):250-2.